# Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

> clinical trial · VERIFIED · 2026-06-11

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Core Binding Factor Acute Myeloid Leukemia

- Company: National Cancer Institute (NCI)
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06917911

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.